Friday, June 06, 2025 | 07:10 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

From DRL to Glenmark, pharma companies see steady revenue growth in Russia

Strong sales in Q4 during war aided by 'stocking up of inventory'

Cipla
premium

Drug firms such as Sun Pharmaceutical Industries, Dr Reddy's Laboratories have significant presence in Russian.

Sohini Das Mumbai
The Russia-Ukraine war has not dampened Indian pharma sales in that market. In fact, firms with a presence in Russia — Sun Pharmaceuticals, Dr Reddy’s Laboratories (DRL), and Glenmark — have posted high double-digit revenue growth during the ongoing crisis.

DRL, for example, posted revenues of Rs 686 crore for Q4, a year-on-year growth of 70 per cent. “Growth majorly attributable to traction in base business and new product launches. Q4 partially benefited due to stocking up and divestment of two non-core brands,” DRL said.

India’s largest drug maker by market share Sun Pharmaceutical Industries has posted a 43 per cent YoY